Your browser doesn't support javascript.
SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccinees.
Geers, Daryl; Shamier, Marc C; Bogers, Susanne; den Hartog, Gerco; Gommers, Lennert; Nieuwkoop, Nella N; Schmitz, Katharina S; Rijsbergen, Laurine C; van Osch, Jolieke A T; Dijkhuizen, Emma; Smits, Gaby; Comvalius, Anouskha; van Mourik, Djenolan; Caniels, Tom G; van Gils, Marit J; Sanders, Rogier W; Oude Munnink, Bas B; Molenkamp, Richard; de Jager, Herbert J; Haagmans, Bart L; de Swart, Rik L; Koopmans, Marion P G; van Binnendijk, Robert S; de Vries, Rory D; GeurtsvanKessel, Corine H.
  • Geers D; Department of Viroscience, Erasmus MC; Rotterdam, the Netherlands.
  • Shamier MC; Department of Viroscience, Erasmus MC; Rotterdam, the Netherlands.
  • Bogers S; Department of Viroscience, Erasmus MC; Rotterdam, the Netherlands.
  • den Hartog G; Centre for Immunology of Infectious Diseases and Vaccines, National Institute for Public Health and the Environment; Bilthoven, the Netherlands.
  • Gommers L; Department of Viroscience, Erasmus MC; Rotterdam, the Netherlands.
  • Nieuwkoop NN; Department of Viroscience, Erasmus MC; Rotterdam, the Netherlands.
  • Schmitz KS; Department of Viroscience, Erasmus MC; Rotterdam, the Netherlands.
  • Rijsbergen LC; Department of Viroscience, Erasmus MC; Rotterdam, the Netherlands.
  • van Osch JAT; Department of Viroscience, Erasmus MC; Rotterdam, the Netherlands.
  • Dijkhuizen E; Department of Viroscience, Erasmus MC; Rotterdam, the Netherlands.
  • Smits G; Centre for Immunology of Infectious Diseases and Vaccines, National Institute for Public Health and the Environment; Bilthoven, the Netherlands.
  • Comvalius A; Department of Viroscience, Erasmus MC; Rotterdam, the Netherlands.
  • van Mourik D; Department of Viroscience, Erasmus MC; Rotterdam, the Netherlands.
  • Caniels TG; Department of Medical Microbiology, Amsterdam UMC; Amsterdam, the Netherlands.
  • van Gils MJ; Department of Medical Microbiology, Amsterdam UMC; Amsterdam, the Netherlands.
  • Sanders RW; Department of Medical Microbiology, Amsterdam UMC; Amsterdam, the Netherlands.
  • Oude Munnink BB; Department of Microbiology and Immunology, Weill Medical College of Cornell University; New York, NY 10021, USA.
  • Molenkamp R; Department of Viroscience, Erasmus MC; Rotterdam, the Netherlands.
  • de Jager HJ; Department of Viroscience, Erasmus MC; Rotterdam, the Netherlands.
  • Haagmans BL; Department of Occupational Health Services, Erasmus MC; Rotterdam, the Netherlands.
  • de Swart RL; Department of Viroscience, Erasmus MC; Rotterdam, the Netherlands.
  • Koopmans MPG; Department of Viroscience, Erasmus MC; Rotterdam, the Netherlands.
  • van Binnendijk RS; Department of Viroscience, Erasmus MC; Rotterdam, the Netherlands.
  • de Vries RD; Centre for Immunology of Infectious Diseases and Vaccines, National Institute for Public Health and the Environment; Bilthoven, the Netherlands.
  • GeurtsvanKessel CH; Department of Viroscience, Erasmus MC; Rotterdam, the Netherlands. r.d.devries@erasmusmc.nl c.geurtsvankessel@erasmusmc.nl.
Sci Immunol ; 6(59)2021 05 25.
Article in English | MEDLINE | ID: covidwho-1243688
ABSTRACT
The emergence of SARS-CoV-2 variants harboring mutations in the spike (S) protein has raised concern about potential immune escape. Here, we studied humoral and cellular immune responses to wild type SARS-CoV-2 and the B.1.1.7 and B.1.351 variants of concern in a cohort of 121 BNT162b2 mRNA-vaccinated health care workers (HCW). Twenty-three HCW recovered from mild COVID-19 disease and exhibited a recall response with high levels of SARS-CoV-2-specific functional antibodies and virus-specific T cells after a single vaccination. Specific immune responses were also detected in seronegative HCW after one vaccination, but a second dose was required to reach high levels of functional antibodies and cellular immune responses in all individuals. Vaccination-induced antibodies cross-neutralized the variants B.1.1.7 and B.1.351, but the neutralizing capacity and Fc-mediated functionality against B.1.351 was consistently 2- to 4-fold lower than to the homologous virus. In addition, peripheral blood mononuclear cells were stimulated with peptide pools spanning the mutated S regions of B.1.1.7 and B.1.351 to detect cross-reactivity of SARS-CoV-2-specific T cells with variants. Importantly, we observed no differences in CD4+ T-cell activation in response to variant antigens, indicating that the B.1.1.7 and B.1.351 S proteins do not escape T-cell-mediated immunity elicited by the wild type S protein. In conclusion, this study shows that some variants can partially escape humoral immunity induced by SARS-CoV-2 infection or BNT162b2 vaccination, but S-specific CD4+ T-cell activation is not affected by the mutations in the B.1.1.7 and B.1.351 variants.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: CD4-Positive T-Lymphocytes / CD8-Positive T-Lymphocytes / Spike Glycoprotein, Coronavirus / SARS-CoV-2 / COVID-19 / Antibodies, Viral Type of study: Cohort study / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines / Variants Limits: Humans Language: English Year: 2021 Document Type: Article Affiliation country: Sciimmunol.abj1750

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: CD4-Positive T-Lymphocytes / CD8-Positive T-Lymphocytes / Spike Glycoprotein, Coronavirus / SARS-CoV-2 / COVID-19 / Antibodies, Viral Type of study: Cohort study / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines / Variants Limits: Humans Language: English Year: 2021 Document Type: Article Affiliation country: Sciimmunol.abj1750